Brian A. Keller

804 total citations
27 papers, 483 citations indexed

About

Brian A. Keller is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Brian A. Keller has authored 27 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Brian A. Keller's work include Virus-based gene therapy research (9 papers), CAR-T cell therapy research (7 papers) and Amyotrophic Lateral Sclerosis Research (5 papers). Brian A. Keller is often cited by papers focused on Virus-based gene therapy research (9 papers), CAR-T cell therapy research (7 papers) and Amyotrophic Lateral Sclerosis Research (5 papers). Brian A. Keller collaborates with scholars based in Canada, United States and United Kingdom. Brian A. Keller's co-authors include John C. Bell, Michael J. Strong, Kathryn Volkening, Cristian A. Droppelmann, Christian R. Hirsch, Lee Cyn Ang, Rosa Rademakers, Danae Campos‐Melo, F Gudat and Carolina S. Ilkow and has published in prestigious journals such as Annals of the New York Academy of Sciences, Science Translational Medicine and Acta Neuropathologica.

In The Last Decade

Brian A. Keller

26 papers receiving 450 citations

Peers

Countries citing papers authored by Brian A. Keller

Since Specialization

Citations

This map shows the geographic impact of Brian A. Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Keller more than expected).

Fields of papers citing papers by Brian A. Keller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Keller. The network helps show where Brian A. Keller may publish in the future.

Co-authorship network of co-authors of Brian A. Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Brian A. Keller. A scholar is included among the top collaborators of Brian A. Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian A. Keller. Brian A. Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiological selectivity and plant–environment feedbacks during Middle and Late Pennsylvanian plant community transitions 2023 ·Geological Society London Special Publications ·Jonathan P. Wilson, Gabriel Oppler, (unknown), (unknown), (unknown), Brian A. Keller	5
2	Molecular Pathogenesis of Penile Squamous Cell Carcinoma: Current Understanding and Potential Treatment Implications 2022 ·Archives of Pathology & Laboratory Medicine ·Brian A. Keller, (unknown), Bernard Lo, Harman Sekhon, Trevor A. Flood	5
3	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation 2021 ·Journal of Cancer Research and Clinical Oncology ·Brian A. Keller, (unknown), Oliver Varette, Aron Broom, (unknown), (unknown), (unknown), (unknown), Bernard Lo, Bruce F. Burns, Carolyn Nessim, Michael Ong, Roberto A. Chica, Harold Atkins, Jean‐Simon Diallo, Carolina S. Ilkow, John C. Bell	2
4	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies 2019 ·Molecular Therapy — Oncolytics ·Dean Fergusson, (unknown), (unknown), (unknown), (unknown), Justin Presseau, Kelly D. Cobey, Jean‐Simon Diallo, Rebecca C. Auer, Jonathan Kimmelman, Natasha Kekre, Nader El-Sayes, Ramya Krishnan, Brian A. Keller, Carolina S. Ilkow, Manoj M. Lalu	12
5	Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition 2019 ·Molecular Therapy ·Victoria A. Jennings, Gina B. Scott, (unknown), Karen J. Scott, G Migneco, Brian A. Keller, (unknown), Oliver Donnelly, Howard Peach, Donald Dewar, Kevin J. Harrington, Hardev Pandha, Adel Samson, Richard G. Vile, Alan Melcher, Fiona Errington‐Mais	47
6	Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses 2019 ·Methods in molecular biology ·Brian A. Keller, (unknown), (unknown), Carolina S. Ilkow	1
7	Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition 2018 ·Science Translational Medicine ·Mohammed Selman, (unknown), (unknown), (unknown), Ramya Krishnan, Larissa A. Pikor, Andrew Chen, Brian A. Keller, Carolina S. Ilkow, John C. Bell, Jean‐Simon Diallo	44
8	Oncolytic Viruses: The Best is Yet to Come 2018 ·Current Cancer Drug Targets ·Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei, John C. Bell	16
9	RNA and Protein Interactors with TDP-43 in Human Spinal-Cord Lysates in Amyotrophic Lateral Sclerosis 2018 ·Journal of Proteome Research ·Kathryn Volkening, Brian A. Keller, Cheryl Leystra‐Lantz, Michael J. Strong	4
10	Oncolytic viruses—immunotherapeutics on the rise 2016 ·Journal of Molecular Medicine ·Brian A. Keller, John C. Bell	46
11	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies 2016 ·Molecular Therapy — Oncolytics ·Laura Evgin, Carolina S. Ilkow, Marie‐Claude Bourgeois‐Daigneault, Christiano Tanese de Souza, Lawton J. Stubbert, Michael S. Huh, Victoria A. Jennings, Monique Marguerie, Sergio A. Acuña, Brian A. Keller, Charles Lefebvre, Theresa Falls, Fabrice Le Bœuf, Rebecca C. Auer, John D. Lambris, J. Andrea McCart, David F. Stojdl, John C. Bell	9
12	Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis 2013 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Cristian A. Droppelmann, Jian Wang, Danae Campos‐Melo, Brian A. Keller, Kathryn Volkening, Robert A. Hegele, Michael J. Strong	29
13	Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis 2012 ·Neurobiology of Aging ·Cristian A. Droppelmann, Brian A. Keller, Danae Campos‐Melo, Kathryn Volkening, Michael J. Strong	32
14	Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism 2012 ·Acta Neuropathologica ·Brian A. Keller, Kathryn Volkening, Cristian A. Droppelmann, Lee Cyn Ang, Rosa Rademakers, Michael J. Strong	100
15	Study Tours: Strategies for Serving Business Students 2009 ·(unknown), Brian A. Keller	1
16	Effects of Student-Centered Teaching on Student Evaluations in Calculus 1999 ·Educational research quarterly ·Brian A. Keller, C. T. Russell, Heather Thompson	1
17	A Large-Scale Study Clarifying the Roles of the TI-92 and Instructional Format on Student Success in Calculus 1999 ·Annals of the New York Academy of Sciences ·Brian A. Keller, C. T. Russell, Heather Thompson	5
18	Whelk-come to Mathematics 1999 ·Mathematics Teacher Learning and Teaching PK-12 ·Brian A. Keller, (unknown)	1
19	Student preferences for representations of functions 1998 ·International Journal of Mathematical Education in Science and Technology ·Brian A. Keller, Christian R. Hirsch	53
20	[Electron microscopy, cytological, and serological studies on the effect of endoxan on the primary and secondary response of the mouse to sheep erythrocytes]. 1974 ·PubMed ·F Gudat, Brian A. Keller, (unknown)	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact